

# Indivior Publications 2019

## Manuscripts

### Treatment of Opioid Use Disorder

1. Ling W, Nadipelli V, Ronquest N, Albright V, Aldridge A, Learned S, Mehra V, Heidbreder C. Remission from Chronic Opioid Use—Studying Environmental and Socio-economic Factors on Recovery (RECOVER): study design and participant characteristics. *Contemp Clin Trials*. 2019;76: 93-103. <https://doi.org/10.1016/j.cct.2018.11.015>
2. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled trial. *The Lancet*. 2019;393(10173):778-790. [https://doi.org/10.1016/S0140-6736\(18\)32259-1](https://doi.org/10.1016/S0140-6736(18)32259-1)
3. Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh Y-C, Learned SM, Mehra V, Heidbreder C. Patient-Centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study. *J Addiction Med*, Epub 2019 Mar 4. <https://doi.org/10.1097/ADM.0000000000000517>
4. Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young, MA (2019) Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. *Clin Pharmacol Ther*, Epub 2019 Feb 22. <https://doi.org/10.1002/cpt.1406>

## Abstracts

### Treatment of Opioid Use Disorder

1. Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Heidbreder C, Learned SM, Mehra V. Impact of RBP-6000 on patient-reported outcomes in patients with opioid use disorder: results of a randomized, placebo-controlled, phase 3 study. *Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting*. San Diego, CA; March 25-28, 2019.
2. Andorn A, Haight B, Greenwald MK, Zhao S, Fox NL, Heidbreder C, Learned SM. Higher abstinence rates with greater buprenorphine exposure among patients who inject opioids. *Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting*. San Diego, CA; March 25-28, 2019.
3. Ling W, Nadipelli VR, Ronquest N, Aldridge CT, Solem N, Peiper S, Learned SM, Heidbreder C. Recovery from OUD following monthly extended-release buprenorphine treatment: 12-month longitudinal outcomes. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
4. Wiest K, van Velzen M, Algra H, Moss L, Dobbins R. High therapeutic buprenorphine levels reduce IV fentanyl respiratory depression. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
5. Andorn A, Boyett B, Shinde S, Fox NL, Zhao Y, Learned SM. Long-term RBP-6000, sustained-release buprenorphine for moderate-to-severe OUD. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.
6. Wiest K, Andorn A, Fox NL, Learned S, Zhao Y, Gray F. Abstinence response to 300mg vs 100mg RBP-6000 among opioid injection users. *Proceedings of the 50th Annual Meeting of the American Society of Addiction Medicine (ASAM)*. Orlando, FL; April 4-7, 2019.

## Treatment of Schizophrenia

1. Thompson S, Andorn A, Nadipelli VR, Graham J, De Veugh-Geiss A, Learned SM, Heidbreder C. The budget impact of PERSERIS™: a once-monthly long-acting injectable (LAI) antipsychotic in patients with schizophrenia. Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting. San Diego, CA; March 25-28, 2019.
2. Thompson S, Andorn A, Nadipelli VR, Graham J, De Veugh-Geiss A, Learned SM, Heidbreder C. The cost-effectiveness of PERSERIS™: a once-monthly long-acting injectable antipsychotic in patients with schizophrenia. Proceedings of the Academy of Managed Care Pharmacy (AMCP) Managed Care and Specialty Pharmacy Annual Meeting. San Diego, CA; March 25-28, 2019.